Nelson R&D drug patent
Executive Summary
Firm said it received a U.S. patent, No. 4,564,628, for "a potent new drug candidate for the treatment of Parkinson's disease, glaucoma, and hyperprolactinemia." Nelson said clinical trials of the compound, known as N-0437, for the treatment of Parkinson's disease and glaucoma are scheduled to begin this year.